Literature DB >> 10556926

Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability.

F Stain-Texier1, G Boschi, P Sandouk, J M Scherrmann.   

Abstract

1 This study was done to find out how morphine 6-beta-D-glucuronide (M6G) induces more potent central analgesia than morphine, despite its poor blood-brain barrier (BBB) permeability. The brain uptake and disposition of these compounds were investigated in plasma and in various brain compartments: extracellular fluid (ECF), intracellular space (ICS) and cerebrospinal fluid (CSF). 2 Morphine or M6G was given to rats at 10 mg kg(-1) s.c. Transcortical microdialysis was used to assess their distributions in the brain ECF. Conventional tissue homogenization was used to determine the distribution in the cortex and whole brain. These two procedures were combined to estimate drug distribution in the brain ICS. The blood and CSF pharmacokinetics were also determined. 3 Plasma concentration data for M6G were much higher than those of morphine, with Cmax and AUC 4-5 times more higher, Tmax shorter, and VZf-1 (volume of distribution) and CL f(-1) (clearance) 4-6 times lower. The concentrations of the compounds in various brain compartments also differed: AUC values for M6G were lower than those of morphine in tissue and CSF and higher in brain ECF. AUC values in brain show that morphine levels were four times higher in ICS than in ECF, whereas M6G levels were 125 higher in ECF than in ICS. 4 Morphine entered brain cells, whereas M6G was almost exclusively extracellular. This high extracellular concentration, coupled with extremely slow diffusion into the CSF, indicates that M6G was predominantly trapped in the extracellular fluid and therefore durably available to bind at opioid receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10556926      PMCID: PMC1571713          DOI: 10.1038/sj.bjp.0702873

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite.

Authors:  D Paul; K M Standifer; C E Inturrisi; G W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  1989-11       Impact factor: 4.030

2.  Morphine-6-glucuronide has high affinity for the opioid receptor.

Authors:  C B Christensen; L N Jørgensen
Journal:  Pharmacol Toxicol       Date:  1987-01

3.  Biochemical basis for analgesic activity of morphine-6-glucuronide. I. Penetration of morphine-6-glucuronide in the brain of rats.

Authors:  H Yoshimura; S Ida; K Oguri; H Tsukamoto
Journal:  Biochem Pharmacol       Date:  1973-06-15       Impact factor: 5.858

4.  Analgesic effect of morphine glucuronides.

Authors:  K Shimomura; O Kamata; S Ueki; S Ida; K Oguri; H Yoshimura; H Tsukamoto
Journal:  Tohoku J Exp Med       Date:  1971-09       Impact factor: 1.848

5.  Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium.

Authors:  J Huwyler; J Drewe; C Klusemann; G Fricker
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

6.  Disposition and analgesic effects of systemic morphine, morphine-6-glucuronide and normorphine in rat.

Authors:  J Hasselström; J O Svensson; J Säwe; Z Wiesenfeld-Hallin; Q Y Yue; X J Xu
Journal:  Pharmacol Toxicol       Date:  1996-07

7.  An improved extraction method for the HPLC determination of morphine and its metabolites in plasma.

Authors:  M Pawula; D A Barrett; P N Shaw
Journal:  J Pharm Biomed Anal       Date:  1993 Apr-May       Impact factor: 3.935

8.  Morphine and morphine metabolite kinetics in the rat brain as assessed by transcortical microdialysis.

Authors:  M Barjavel; P Sandouk; M Plotkine; J M Scherrmann
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

9.  Species difference of site-selective glucuronidation of morphine.

Authors:  C K Kuo; N Hanioka; Y Hoshikawa; K Oguri; H Yoshimura
Journal:  J Pharmacobiodyn       Date:  1991-04

10.  The analgesic activity of morphine-6-glucuronide.

Authors:  R Osborne; P Thompson; S Joel; D Trew; N Patel; M Slevin
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

View more
  23 in total

1.  Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats--pharmacokinetic/pharmacodynamic modelling.

Authors:  M R Bouw; R Xie; K Tunblad; M Hammarlund-Udenaes
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 2.  How to measure drug transport across the blood-brain barrier.

Authors:  Ulrich Bickel
Journal:  NeuroRx       Date:  2005-01

3.  Blood-brain distribution of morphine-6-glucuronide in sheep.

Authors:  H H Villesen; D J R Foster; R N Upton; L L Christrup; A A Somogyi; A Martinez; C Grant
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

4.  Induction of morphine-6-glucuronide synthesis by heroin self-administration in the rat.

Authors:  Maria Meringolo; Valentina Brusadin; Maria T De Luca; Christian Montanari; Christian L Montanari; Letizia Antonilli; Paolo Nencini; Aldo Badiani
Journal:  Psychopharmacology (Berl)       Date:  2011-10-21       Impact factor: 4.530

5.  Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.

Authors:  Jun Shen; Angel M Carcaboso; K Elaine Hubbard; Michael Tagen; Henry G Wynn; John C Panetta; Christopher M Waters; Mohamed A Elmeliegy; Clinton F Stewart
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

6.  Computational framework for predictive PBPK-PD-Tox simulations of opioids and antidotes.

Authors:  Carrie German; Minu Pilvankar; Andrzej Przekwas
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-08-08       Impact factor: 2.745

7.  HPLC with laser-induced native fluorescence detection for morphine and morphine glucuronides from blood after immunoaffinity extraction.

Authors:  Y Hupka; J Beike; J Roegener; B Brinkmann; G Blaschke; H Köhler
Journal:  Int J Legal Med       Date:  2005-01-19       Impact factor: 2.686

8.  Blood-brain barrier permeability and brain uptake mechanism of kainic acid and dihydrokainic acid.

Authors:  Mikko Gynther; Aleksanteri Petsalo; Steen H Hansen; Lennart Bunch; Darryl S Pickering
Journal:  Neurochem Res       Date:  2014-12-09       Impact factor: 3.996

9.  Different distribution of morphine and morphine-6 beta-glucuronide after intracerebroventricular injection in rats.

Authors:  Takashi Okura; Masanori Saito; Misato Nakanishi; Noriyuki Komiyama; Aki Fujii; Shizuo Yamada; Ryohei Kimura
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

Review 10.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.